Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues - PubMed (original) (raw)

Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues

Anna Sapino et al. Front Oncol. 2013.

Abstract

HER2 overexpression and anti-HER2 agents represent probably the best story of success of individualized therapy in breast cancer. Due to the important therapeutic implications, the issue under the spotlight has been, since ever, the correct identification of true HER2 positivity on tissue specimens. Eligibility to anti-HER2 agents is strictly dependent on the demonstration of HER2 overexpression (by immunohistochemistry) or of HER2 gene amplification by in situ techniques (fluorescence in situ hybridization, FISH), however there are controversial issues involving cases with "equivocal" HER2 status based on conventional techniques (about 20% of specimens). In terms of HER2 expression a major debate is the presence of full-length and truncated forms of the protein and controversial clinical data have been reported on the therapeutic implications of these HER2 fragments. In terms of HER2 gene assessment, the occurrence of amplification of the chromosome 17 centromeric region (CEP17) has been proven responsible for misleading HER2 FISH results, precluding anti-HER2 based therapy to some patients. Finally HER2 activating mutations have been recently described as a biological mechanisms alternative to HER2 gene amplification. In this review we will focus on the controversies that pathologists and oncologists routinely face in the attempt to design the most tailored treatment for breast cancer patients. We will focus on the HER2 gene and on the protein, both at technical and interpretational levels.

Keywords: CEP17 amplification; HER2; HER2 mutations; diagnosis; test; therapy; truncated HER2.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Steric hindrance phenomenon. Immunohistochemistry for the trastuzumab binding site (BiotHER staining) shows higher intensity in cell block sections of BT474 cells treated with 0.1% pronase and in pronase-treated (as “antigen retrieval”) cell block sections of BT474 cells. This is likely to be due to a matter of steric hindrance, according to which if antigen molecules are closely “packed” on the cell surface, spatial interference results in a greater likelihood of reduced antibody binding.

Figure 2

Figure 2

Chromosome 17 polysomy versus CEP17 gain/amplification. Possible scenarios in which additional CEP17 signals are encountered, from top to bottom: true chromosome 17 (chr17) polysomy without HER2 gene amplification; gain/amplification of CEP17 without HER2 amplification; HER2 amplification in a context of chr17 polysomy; HER2 amplification coupled with CEP17 gain/amplification. In all scenarios the ratio is below 2.2, however in the latter two cases HER2 amplification is present (HER2 mean copy number >6).

Similar articles

Cited by

References

    1. Anido J., Scaltriti M., Bech Serra J. J., Santiago Josefat B., Todo F. R., Baselga J. (2006). Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234–324410.1038/sj.emboj.7601191 - DOI - PMC - PubMed
    1. Arribas J., Baselga J., Pedersen K., Parra-Palau J. L. (2011). p95HER2 and breast cancer. Cancer Res. 71, 1515–151910.1158/0008-5472.CAN-10-3795 - DOI - PubMed
    1. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K. K., Carter S. L., Frederick A. M. (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–40910.1038/nature11154 - DOI - PMC - PubMed
    1. Baselga J., Cortes J., Kim S. B., Im S. A., Hegg R., Im Y. H. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–11910.1056/NEJMoa1109653 - DOI - PMC - PubMed
    1. Birner P., Oberhuber G., Stani J., Reithofer C., Samonigg H., Hausmaninger H. (2001). Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin. Cancer Res. 7, 1669–1675 - PubMed

LinkOut - more resources